Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease?
- 11 February 1991
- journal article
- Published by Elsevier in Neuroscience Letters
- Vol. 123 (1) , 115-118
- https://doi.org/10.1016/0304-3940(91)90171-o
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The evolution and distribution of morphological changes in the nervous system of the common marmoset following the acute administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridineMovement Disorders, 1989
- Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's DiseaseNew England Journal of Medicine, 1988
- The neurotoxicity of 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine (mptp) and its relevance to parkinson's diseaseNeurochemistry International, 1987
- Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on catecholamines and metabolites in primate brain and CSFBrain Research, 1987
- Suboccipital puncture for cerebrospinal fluid in the common marmoset (Callithrix jacchus)Laboratory Animals, 1987
- Permanent human parkinsonism due to 1‐methy 1–4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP)Neurology, 1985
- The Clinical Syndrome of Striatal Dopamine DeficiencyNew England Journal of Medicine, 1985
- Mechanism of MPTP toxicity: more answers, more questionsTrends in Pharmacological Sciences, 1985
- Altered serotonin metabolism in depressed patients with Parkinson's diseaseNeurology, 1984
- Brain dopamine and the syndromes of Parkinson and Huntington Clinical, morphological and neurochemical correlationsJournal of the Neurological Sciences, 1973